Tirzepatide Supply in the UK: What Patients Actually Need to Know

You ordered. Now you're waiting for a pen that hasn't arrived.

This is the scenario thousands of people in the UK have faced since Mounjaro became available privately. The surge in demand for tirzepatide has been extraordinary, a medicine that activates both GIP and GLP-1 receptors, producing average weight reductions of around 20% at the highest dose in the SURMOUNT-1 trial, drew patients faster than any single manufacturer could scale production. Eli Lilly has invested heavily in manufacturing capacity, but shortfalls have appeared at unpredictable points across the strength range. The 2.5mg pen (the dose everyone starts on to let their body adjust) has been particularly affected at times, because every new patient needs it before they can progress anywhere on the schedule.

What this means practically: a pharmacy sourcing through the licensed UK supply chain will sometimes have strong stock of the 5mg and 7.5mg strengths while the 2.5mg is constrained, or vice versa. Availability varies week to week, not month to month. A pharmacy that tells you stock is guaranteed for every strength, indefinitely, is telling you something that doesn't match reality. Our prescribers flag this honestly at consultation and before every repeat, which is the right clinical approach, not a workaround.

The Mounjaro supply issues in the UK page covers the history of these disruptions in more detail if you want the fuller picture.

Why the source of your tirzepatide matters as much as the pen itself

When a medicine is in short supply, counterfeit versions move in to fill the gap. The MHRA has warned publicly and repeatedly about fake weight-loss pens sold via social media and unverified online sellers, in October 2025, the agency raided the UK's first illicit manufacturing site producing counterfeit tirzepatide pens, in Northampton, and has seized approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million. Some counterfeit pens have contained insulin. The consequences of injecting the wrong substance can be severe.

The only safe route is a pharmacy you can verify. Every legitimate UK pharmacy dispensing prescription-only medicines is listed on the GPhC register, you can check any pharmacy at pharmacyregulation.org, including our own premises registration number 9012878. Sellers offering tirzepatide without requiring a prescription, or those using discount codes as an incentive, are red flags. A prescription medicine cannot be legally sold without clinical assessment, full stop. If the price seems implausibly low, that is not a deal, it is a warning.

You can also report any seller you suspect of supplying medicines illegally through the MHRA's Yellow Card scheme, which handles both side-effect reports and concerns about counterfeit or unlicensed supply.

How a regulated pharmacy manages tirzepatide supply for existing patients

For people already on treatment, supply disruption raises a specific worry: what happens to your dose schedule if a pen isn't available? Titration timing matters clinically. Missing a dose or staying at a lower strength longer than intended is not automatically harmful, but it is something your prescriber should know about and manage. A responsible pharmacy does not dispatch a different strength without clinical review, and it does not leave patients in the dark about delays.

At nume, every repeat order goes back in front of a GPhC-registered prescriber before anything is sent. That review confirms the next strength is appropriate, checks whether anything has changed in your health picture, and accounts for current stock. Orders placed before 12pm on a working day are dispatched the same day once approved, via DPD, you get a tracking notification and the pen arrives the next working day in plain, unbranded packaging. You can find out more about how Mounjaro supply works in the UK and the steps involved in getting it through a regulated route.

If you're considering a longer run of treatment to reduce the frequency of reordering, our Mounjaro 3 months supply page explains what's clinically and practically possible, and patients who want to plan even further ahead can find details about getting a Mounjaro 3 month supply in the UK, including what that involves from a prescribing and stock perspective. Cost context for ongoing treatment is covered on our weight-loss treatments overview.

What the NHS tirzepatide rollout means for private supply

Tirzepatide was recommended by NICE in December 2024 (Technology Appraisal TA1026) for NHS use in adults with a BMI of 35 or above and at least one weight-related comorbidity, with phased rollout by eligibility cohort. NHS access through GP practices became possible from April 2026 under the new GP contract, though individual practice participation varies. The NICE recommendation and the phased NHS rollout are covered in detail on the Mounjaro overview page.

The practical consequence for supply is that NHS commissioning adds another substantial source of demand on the same licensed UK supply chain. Private and NHS supply draw from the same manufacturer. As NHS volumes grow, the pressure on stock does not shrink, which makes sourcing through a GPhC-registered pharmacy with genuine supply chain relationships all the more important. If you want to understand whether you might qualify through the NHS or whether private treatment suits your situation better, our prescribers can talk through both at your free consultation.